Chapter 176 Bode-001 AIDS Specific Drug
As for the 'Bode-001 AIDS specific drug' compared to the 'EBT-002 gene medical drug' of Xingtu Gene Company, which one is better or worse, which one is stronger or weaker?

First of all, the Broad Institute's 'Bode-001 AIDS specific drug' is a qualified drug.

It is a gene-editing drug that can completely eliminate all HIV viruses in the body of an AIDS patient, so it is a qualified drug.

Under such circumstances, it was naturally destined that he would pose a huge threat to Xingtu Gene Company's 'EBT-002 Gene Medical Drug' and rob Xingtu Gene Company of its profits.

Therefore, the next competition will be about who has more advantages and who has fewer disadvantages, and ultimately let consumers choose which company's specific AIDS drug to use.

The biggest drawback of the 'EBT-002 gene therapy drug' is that its manufacturing cost is very high and it is difficult to significantly reduce the cost.

After all, each 'RNP complex' is produced using chemical synthesis methods. Not only are the machines expensive, but it also requires hundreds of procedures, so the cost is naturally very high.

The technology used by the Broad Institute's 'Bode-001 AIDS specific drug' is the viral transformation method.

The advantage of this viral transformation method is that once an artificial virus is successfully edited, the virus itself can multiply and reproduce.

At this time, it is really easy to mass-produce, the production cost is very low, and the R&D cost is slightly lower than the 'RNP complex' line, so the final net profit is naturally higher.

As for the disadvantage of the viral transformation method, it is that viruses are foreign objects after all and will trigger a certain immune response in the human immune system.

At that time, pain, numbness, itching, fever, chills, etc. are common conditions. There is also the possibility of excessive immune response and sudden death.

In addition, there is a potential hidden danger that endangers all mankind. This hidden danger is that the virus can usually survive for 3 or 5 days.

The artificial viruses created through artificial editing are meant to be effective and achieve the purpose of transforming cells throughout the body, rather than being killed immediately by the human immune system upon injection.

The designers of artificial viruses will certainly take advantage of the shortcomings of the human immune system and cellular defense system and try to reduce the response of the human immune system and cellular defense system.

Therefore, the designer of the artificial virus is equivalent to the bandit’s guide, allowing the bandits to understand the situation inside the village.

This allowed the bandits to quietly avoid the numerous defenses and traps, and eventually sneak into the village to kill people.

If we convert bandits into artificial viruses, they are artificially designed viruses that can significantly or even perfectly reduce the body's immune response, allowing the artificial virus to directly reach the cells and even the cell nucleus.

In this case, this specially designed artificial virus, once it mutates out of control, can perfectly evade and bypass the human immune system.

Its horror is not much less than that of the Ebola virus. After all, this man-made virus can perfectly avoid and overcome the defenses of the human immune system.

As for the probability of mutation getting out of control, no one can guarantee it.

All we can say is that the more people are injected, the larger the base number, and the greater the probability of mutation getting out of control. In addition, it also has a certain relationship with the survival time of the artificial virus.

In other words, when the base number of injectors reaches an extremely large number, the artificial virus will definitely mutate out of control.

If the epidemic prevention and control work is not done well at that time and the spread of the mutated man-made virus is not contained, it will be a disaster affecting all mankind.

As for what level this disaster will reach, no one can be sure.

After all, the mutated artificial virus may have limited transmission routes. It cannot be transmitted through coughing, but can only be transmitted through limbs or blood.

Of course, in addition to the hidden dangers that this artificial virus mutation may pose to all of humanity, there are actually other hidden dangers for individuals.

This is because viruses cannot guarantee 100% stability and accuracy when replicating themselves.

The Cas9 protein produced by artificial viruses may also attack the genetic fragments of normal cells.

This behavior will naturally bring certain hidden dangers to the human body, so the virus transformation method has many cost advantages, but the risk is also quite high.

In contrast, the disadvantages of the 'Bode-001 AIDS specific drug' that uses the viral transformation method are the advantages of Starway Gene's 'EBT-002 Gene Medical Drug'.

The advantage of the 'EBT-002 gene therapy drug' is that it is highly safe, and the RNP complex is not a virus at all. Naturally, there is no possibility of viral mutation. Finally, because it slightly repairs the genetic defects of the injector, it can be treated once and will never be infected with AIDS again.

It can be said that apart from the high cost, the 'EBT-002 gene medical drug' has no other major disadvantages and is full of advantages.

Of course, the high cost is actually nothing, because you can tell with a little thought that the Broad Institute's "Bode-001 AIDS specific drug" is definitely not cheap.

After all, dozens of investment companies on Wall Street and major global pharmaceutical giants invested a total of $350 billion in the Broad Institute alone.

The purpose is to produce the current result, 'Bode-001 AIDS specific drug'. Under such circumstances, they naturally would not sell 'Bode-001 AIDS specific drug' at a bargain price.

Therefore, their advantage of low cost cannot be reflected, and naturally cannot bring a fatal impact to Xingtu Technology.

Of course, there was no fatal impact, but there was definitely a huge impact.

After all, their production costs are cheap, so even if the price of the AIDS-specific drug is reduced by a few hundred yuan, their profits will be the same as those of Starway Gene Company, with a large price reduction range.

In addition, they have the right to speak for overseas television stations, newspapers and even local Internet media.

So they can hype up the benefits of 'Bode-001 AIDS specific drug' and avoid the disadvantages.

They may even try to belittle or slander Xingtu Technology's 'EBT-002 Gene Medical Drug' by saying it is unsafe, that someone was injected with the drug and died, and so on.

In this world where public opinion can make something false seem true, this is the benefit of having the right to speak.

In addition, they can also suppress Xingtu Gene through public opinion or other pressures, such as directly preventing Xingtu Gene's drugs from being listed overseas.

At this time, as the West has developed an effective AIDS drug that can replace Star Path Gene Company's, Star Path Gene Company will definitely face a huge shock.

Of course, these methods have not yet been implemented, but Lin Feng is inferring the possibilities based on the news he has seen.

After all, at this time, as the Broad Institute announced the successful development of the AIDS-specific drug 'Bode-001 AIDS-specific drug', countless media around the world praised them to the sky.

He praised the Broad Institute for being amazing, calling it the world's strongest genetic research and development company, and he also praised how awesome the 'Bode-001 AIDS drug' was.

Among them, none of the shortcomings and disadvantages of "Bode-001 AIDS specific drug" were mentioned.

Of course, along with the news release of the great success of the Bode Institute, medical departments in various countries overseas have also announced that they will officially accelerate the review of the "Bode-001 AIDS specific drug" so that everyone can treat AIDS as soon as possible.

Among them, Xingtu Technology's "EBT-002 Gene Medical Drug" seemed to have been forgotten, and there was no mention of speeding up the approval process.

It has been more than two months since the application for clinical trial of 'EBT-002 Gene Medical Drug' was made. As a result, except for Daxia and a few unknown small countries, the approval was accelerated.

Those big countries with some fame, such as the Kingdom of Transvestite, South Vietnam, India and other countries have not approved the clinical trial application of "EBT-002 Gene Medical Drug" at all, and the date of its launch is nowhere in sight.

At this time, the 'Bode-001 AIDS specific drug' developed by the Broad Institute of the United States could be developed easily and the approval process could be accelerated.

Judging from their appearances, it may only take a month or two for the product to be officially launched on the market. This kind of differential treatment is really regrettable.

"According to this trend, I'm afraid that all AIDS patients in the world will be cured, and our 'EBT-002 gene therapy drug' will not be available overseas.

Is this the power of capital? It is indeed a headache.

This despicable method of "I have defeated you, but I can make it impossible for you to go public" is indeed very effective."

Estimating the future situation, Lin Feng felt a bit of a headache.

(End of this chapter)